StockNews.com Lowers Alimera Sciences (NASDAQ:ALIM) to Hold

Alimera Sciences (NASDAQ:ALIM) was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating in a report released on Friday.

Separately, Maxim Group initiated coverage on Alimera Sciences in a research note on Monday, March 25th. They set a “buy” rating and a $10.00 price objective on the stock.

Alimera Sciences Trading Down 8.6 %

Shares of Alimera Sciences stock traded down $0.33 during trading on Friday, hitting $3.52. 56,087 shares of the company were exchanged, compared to its average volume of 80,829. The firm has a market capitalization of $184.29 million, a P/E ratio of -1.63 and a beta of 1.18. The firm’s fifty day moving average price is $3.76 and its 200 day moving average price is $3.60. The company has a debt-to-equity ratio of 1.40, a current ratio of 2.39 and a quick ratio of 2.31. Alimera Sciences has a 1-year low of $1.56 and a 1-year high of $4.38.

Alimera Sciences (NASDAQ:ALIM) last issued its quarterly earnings data on Thursday, March 7th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.09). The firm had revenue of $26.31 million for the quarter, compared to analyst estimates of $25.10 million. Alimera Sciences had a negative net margin of 24.93% and a negative return on equity of 130.90%. During the same quarter in the prior year, the firm posted ($0.54) EPS. As a group, sell-side analysts expect that Alimera Sciences will post 0.03 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Alimera Sciences

Several institutional investors and hedge funds have recently modified their holdings of ALIM. Osaic Holdings Inc. bought a new position in Alimera Sciences in the second quarter valued at approximately $34,000. Millennium Management LLC bought a new stake in Alimera Sciences in the 4th quarter valued at $32,000. Tower Research Capital LLC TRC boosted its stake in Alimera Sciences by 291.8% in the 3rd quarter. Tower Research Capital LLC TRC now owns 12,000 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 8,937 shares during the period. Northern Trust Corp bought a new position in Alimera Sciences during the 4th quarter worth about $61,000. Finally, Citadel Advisors LLC acquired a new stake in shares of Alimera Sciences in the 4th quarter valued at about $86,000. 99.83% of the stock is currently owned by institutional investors and hedge funds.

Alimera Sciences Company Profile

Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).